WO2003006024A1 - Medicament contenant un derive de pyrimidine - Google Patents
Medicament contenant un derive de pyrimidine Download PDFInfo
- Publication number
- WO2003006024A1 WO2003006024A1 PCT/JP2002/007060 JP0207060W WO03006024A1 WO 2003006024 A1 WO2003006024 A1 WO 2003006024A1 JP 0207060 W JP0207060 W JP 0207060W WO 03006024 A1 WO03006024 A1 WO 03006024A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituted
- compound
- formula
- alkyl group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a drug for central illness (especially Alzheimer's disease) containing a pyrimidine derivative as an active ingredient, or a microglia that is activated.
- a drug for central illness especially Alzheimer's disease
- a pyrimidine derivative for the treatment of central illness (particularly Alzheimer's disease) or Alzheimer's disease in which microglia is activated (particularly those in which microglia is activated by amyloid) using a drug, a pyrimidine derivative
- the present invention relates to the use of a pyrimidine derivative for the manufacture of a medicament for a central disease (particularly Alzheimer's disease) or a medicament for microglia-activated Alzheimer's disease (particularly, those in which microglia is activated by amyloid).
- microdalia activated in vitro by lipopolysaccharide (LPS) and cytosine can produce NO and cause neurotoxicity. It has been reported that some factors produced or exerted toxicity only on neurons and had no effect on astrocyte sites, oligodendrocyte sites, and Schwann cells. Also, during the formation of senile plaques, microglia may be involved in the progression from non-cytotoxic diffuse plaques to compact plaques in which peripheral neurons are degenerating. Some reports suggest gender. Furthermore, it has been reported that microdary is activated by A, suggesting that microglia activation may be widely involved in neurodegeneration in Alheimer's disease.
- LPS lipopolysaccharide
- cytosine can produce NO and cause neurotoxicity. It has been reported that some factors produced or exerted toxicity only on neurons and had no effect on astrocyte sites, oligodendrocyte sites, and Schwann cells. Also, during the formation of senile plaques, microglia may be involved in the progression from non
- a compound that suppresses the activation of microglia by A3 is expected to be effective as a therapeutic or preventive drug for Alzheimer's disease.
- the pyrimidine derivative which is the active ingredient of the present invention, exhibits a vasodilatory effect and a blood pressure lowering effect (JP-A-51-141896, JP-A-52-116497 and Med. Chem. 1980, 23, 927-937), and its activity in improving pollutants (JP-A-2-76880) was known, but its effect as a drug for central illness was not known.
- pyrimidine derivatives or pharmacologically acceptable salts thereof have excellent central illness (particularly Alzheimer's disease) drugs and microglia.
- the present inventors have found that they have an action as a drug for activated Alzheimer's disease (particularly those in which microdalia is activated by j3 amyloid), and completed the present invention.
- the present invention provides the following general formula (I)
- R 1 represents a hydrogen atom or a C, -C 6 alkyl group
- R 2 represents an -alkyl group or a C 3 -C 6 cycloalkyl group
- A represents a formula CH group, a carbon atom or a nitrogen atom substituted with a halogen atom
- D represents a C r C 6 alkylene group or a C, -C 6 alkylene group substituted with a halogen atom
- E represents a group of the formula CH 2 or a group of the formula CHR 3 (wherein, R 3 represents an -alkyl group; ), A carbon atom substituted by a CH group or a C, -C 6 alkyl group;
- Arom is an aryl group, an aryl group substituted with 1 to 3 same or different substituents selected from ⁇ substituent group ⁇ >, a heteroaryl group, or a substituent selected from ⁇ substituent group ⁇ >.
- a drug for central illness containing a compound represented by the formula or a pharmacologically acceptable salt thereof as an active ingredient, Alzheimer's disease in which microglia is activated (particularly, microglia is activated by iS amyloid. It is a drug that has been activated.
- RR 2 , E and “C, -C 6 alkyl group” in ⁇ substituent group ⁇ > include, for example, methyl, ethyl, propyl, isopropyl, butyl, isoptyl, s -Butyl, t-butyl, pentyl, isopentyl, 2-methylbutyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 3,3-dimethyl A straight chain having 1 to 6 carbon atoms such as butyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, and 2-ethylbutyl.
- a chain or branched chain alkyl group preferably a straight or branched chain alkyl group having 1 to 4 carbon atoms, and more preferably, It is a methyl group.
- the “C 3 -C 6 cycloalkyl group” for R 2 is, for example, a 3- to 6-membered saturated cyclic hydrocarbon group such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. It is preferably a 3- to 4-membered saturated cyclic hydrocarbon group, and more preferably a cyclopropyl group.
- D and the “halogen atom” in the ⁇ substituent group ⁇ > are a fluorine atom, a chlorine atom, a bromine atom or an iodine atom, preferably a fluorine atom or a chlorine atom. It is.
- the term "rc, -C 6 alkylene group for D” means, for example, methylene, methylmethylene (—CH (CH 3 ) —), dimethylmethylene (one C (CH 3 ) 2 —), Straight or branched chain with 1 to 6 carbon atoms such as ethylene, propylene, trimethylene, tetramethylene, 1-methyltrimethylene, 2-methyltrimethylene, 3-methyltrimethylene, pentamethylene, hexamethylene; Examples thereof include a branched alkylene group, preferably a linear or branched alkylene group having 1 to 4 carbon atoms, more preferably a methylene, ethylene or methylmethylene group.
- examples of the "aryl group in Arom” include aromatic hydrocarbon groups having 6 to 14 carbon atoms such as phenyl, indenyl, naphthyl, phenanthrenyl and anthracenyl. And preferably a phenyl group.
- the “heteroaryl group” in A rom includes, for example, furyl, chenyl, pyrrolyl, azepinyl, pyrazolyl, imidazolyl, thioxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3-oxazidi Azoriru, Bok Riazoriru, Te Bok Razoriru, thiadiazolyl, Biraniru, pyridyl, pyridazinyl, pyrimidinyl, sulfur atom, such as Birajiniru, oxygen atom or / / and nitrogen atoms from 1 to 4 carbon containing 5 to 7-membered aromatic heterocyclic group And preferably a pyridyl group.
- the “C, -C 6 alkyloxy group” in ⁇ Substituent group 0;> refers to a group in which the C, -C 6 alkyl group J is bonded to an oxygen atom.
- R 2 is a cyclopropyl group or a methyl group
- a rom is a phenyl group or a phenyl group substituted with a halogen atom
- a rom is a phenyl group, an o-chlorophenyl group or an o-fluorophenyl group
- central disease examples include, for example, Alzheimer's disease, depression, Parkinson's disease, Huntington's disease, Pick's disease, developmental dyskinesia, threatening disorder, and panic disorder. Alzheimer's disease.
- Another embodiment of the present invention relates to a method for treating central illness (particularly Alheimer's disease) using a compound having the formula (I) or Alzheimer's disease (particularly) in which microglia is activated.
- central illness particularly Alheimer's disease
- a compound having the formula (I) or Alzheimer's disease particularly in which microglia is activated.
- dairy animals especially humans.
- a further aspect of the present invention relates to microglial activation using a compound having the above formula (I) It is a method of suppressing.
- Still another embodiment of the present invention relates to a drug for central disease (particularly Alzheimer's disease) or Alzheimer's disease in which microglia is activated (particularly those in which microglia is activated by / 8 amyloid).
- a drug for central disease particularly Alzheimer's disease
- microglia is activated
- / 8 amyloid particularly those in which microglia is activated by / 8 amyloid.
- Me represents a methyl group
- cPr represents a cyclopropyl group
- P represents a phenyl group.
- preferred compounds are Compound Nos. 2, 3, 5, 6, 8, 9, 14 15, 20, 21, 26, 27, 32, 33, 38, 39, 44, 45, 50, 51, 56, 57, 62, 63 , 68, 69, 74, 75, 80, 81, 86, 87, 92, 93, 98, 99, 104, 105, 110, 1 1 1, 1 1 6, 1 1 7, 1 2 2, 1 2 3, 1 2 8, 1 2 9, 1 3 4, 1 3 5, 1 4 0, 1 4 1, 1 4 6, 1 4 7 , 15 2, 15 3, 15 8, 15 9, 16 4, 16 5, 17 0 and 17 1, more preferably 2, 5, 8, 9, 1 5, 2 1, 2 7, 3 3, 3 9, 4 5, 5 1, 5 7, 6 3, 6 9, 7 5, 8 1, 8 7, 9 3, 9 9, 10 5, 1 11 1, 11 7, 12 3, 12 9, 13 5, 14 1, 14 7, 15 3, 15 9 and 16 5, and even more preferably Compound Nos. 2, 5, 8, 9, 14, 20, 50,
- the pharmacologically acceptable salt of the compound having the formula (I) of the present invention is an acid addition salt, for example, a hydrofluoride, hydrochloride, hydrobromide or hydroiodide Inorganic salts such as nitrates, perchlorates, sulfates or phosphates; fluorine atoms such as methanesulphonate, trifluoromethanesulphonate or ethanesulphonate Lower alkane sulfonates which may be substituted with: aryl sulfonates such as benzene sulfonate or p-toluene sulfonate; acetate, malate, fumarate, succinate, Organic acid salts such as citrate, tartrate, oxalate or maleate; or glycine, lysine, arginine, ordinine, glutamate or aspara ⁇ amino acid salts such as phosphate salts.
- the compound (I) of the present invention can also exist as a solvate including a hydrate, and the present invention also includes those solvates.
- the compound (I) of the present invention may have an asymmetric carbon, and in such a case, the present invention also encompasses optical isomers and isomer mixtures containing these in any proportion.
- the compound having the formula (I) of the present invention is disclosed in JP-A-51-141896, JP-A-2-76880, JP-A-2-76880 or According to the production method described in Med. Chem. 1980, 23, 927-937, in particular, the compound of (Compound No. 9) is designated as Compound 68 of J. Med. Chem. 1980, 23, 927-937 (Compound No. The compound of 8) was obtained as Example 45 in JP-A-51-141896, and the compound of (Compound No. 14) was obtained in The compound of (Compound No. 2) as Example 44 in JP-A-5-141 896 is easily produced according to the production method described in Example 1 of JP-A-2-76880. You.
- the compound of the present invention having the above formula (I) or a pharmaceutically acceptable salt thereof is used as a medicament, especially for the above-mentioned uses, it may be used as such or a suitable pharmaceutically acceptable excipient.
- Tablets, capsules, granules, powders or syrups orally, or by injection, suppository, patch, or external preparation, etc. Can be administered.
- These preparations may contain excipients (eg, lactose, sucrose, glucose, sugar derivatives such as mannitol, sorbitol; corn starch, potato starch, ⁇ -starch, starch derivatives such as dextrin; crystalline cellulose such as Cellulose derivatives; arabia gum; dextran; organic excipients such as pullulan; and silicate derivatives such as light anhydrous silicic acid, synthetic aluminum silicate, calcium silicate, magnesium metasilicate magnesium; calcium hydrogen phosphate Phosphates such as calcium carbonate; inorganic excipients such as sulfates such as calcium sulfate; and lubricants (eg, stearic acid, calcium stearate, stearic acid).
- excipients eg, lactose, sucrose, glucose, sugar derivatives such as mannitol, sorbitol; corn starch, potato starch, ⁇ -starch, starch derivatives such as dextrin
- Binders eg, hydroxypropylcellulose, hydroxypropylmethylcellulose
- disintegrants eg, low-substituted hydroxypropylcellulose, carboxymethylcellulose, carboxymethylcellulose calcium, internal Crosslinked carboxymethyl cellulose sodium
- Cellulose derivatives such as carboxymethyl starch, sodium carboxymethyl starch, and chemically modified starch celluloses such
- colloidal clay Such as colloidal clay; magnesium hydroxide, aluminum hydroxide Metal hydroxides such as sodium; anionic surfactants such as sodium lauryl sulfate and calcium stearate; cationic surfactants such as benzalkonium chloride; and polyoxyethylene alkyl ether, polyoxy Examples include nonionic surfactants such as ethylene sorbitan fatty acid esters and sucrose fatty acid esters. ), Stabilizers (para-hydroxybenzoic acid esters such as methylparaben and propylparaben; alcohols such as chlorobutanol, benzyl alcohol and phenylethyl alcohol; benzalkonium chloride; phenol and cresol).
- Stabilizers para-hydroxybenzoic acid esters such as methylparaben and propylparaben
- alcohols such as chlorobutanol, benzyl alcohol and phenylethyl alcohol
- benzalkonium chloride phenol and cresol
- Phenols Phenols; thimerosal; dehydroacetic acid; and sorbic acid.
- Flavoring agents for example, commonly used sweetening agents, souring agents, flavoring agents, etc.
- It is manufactured by a well-known method using additives such as a diluent.
- the amount used depends on the symptoms, age, etc., but is usually lower than I mg (preferably 5 mg) and upper limit 1 OOO mg (preferably 500 mg) per adult. On the other hand, it can be administered 1 to 6 times a day depending on symptoms.
- Compound BJ Compound No. 8 (hereinafter, referred to as “Compound BJ”)
- Compound CJ Compound No. 4 (hereinafter referred to as “Compound CJ”)
- Compound DJ Compound No. 1 4 6 (hereinafter referred to as “Compound DJ”)
- Compound EJ Compound No. 1 2 2 (hereinafter referred to as “Compound EJ”)
- Compound FJ Compound No. 7 4 (hereinafter, referred to as “Compound FJ”)
- Compound G Compound No. 50 (hereinafter, referred to as “Compound G”)
- Compound I Compound No. 53 (hereinafter referred to as “Compound I”)
- Compound JJ Compound No. 98 (hereinafter referred to as “Compound JJ”)
- Compound number 20 (hereinafter, referred to as “compound KJ”) was used.
- Mouse peritoneal macrophages used as a substitute for Microdary were prepared as follows. That is, a mouse (C3H / He, N, male, 7-10 weeks old: Japan SLC) was dislocated to the cervical vertebra, sprayed with 10% ethanol, the abdominal skin was cut open leaving the muscle layer, and a 24 G injection needle was inserted. Using PBS 5-7 ml of (Phosphate buffered saline) was intraperitoneally injected into the abdominal cavity, and after thoroughly squeezing the back, the infused solution was drawn up from the abdominal cavity using a 23 G injection needle.
- PBS 5-7 ml of (Phosphate buffered saline) was intraperitoneally injected into the abdominal cavity, and after thoroughly squeezing the back, the infused solution was drawn up from the abdominal cavity using a 23 G injection needle.
- the cells in the collected solution are spun down (900 rpm, 5 minutes), washed with PBS, and then cultured (DMEM (Sigma), 10% FBS (GIBC0), 100 U / ml penici II in + 100 ⁇ l). , g / ml streptomycin (Sigma Co.)) 8x10Vwel I at 96 Anama were seeded into microphone port play Bok 37 ° C in, were cultured in 53 ⁇ 4 C0 2 / 953 ⁇ 4 air Inkyubeta within one. Nitric oxide production was used as an indicator of macrophage activation.
- the activity of the compound was evaluated by 1) the concentration at which the absorbance in the presence of 2) ⁇ ) 8 and the absorbance in the presence of the test compound became 50 ⁇ ⁇ ⁇ ⁇ with respect to the absorbance when only Aj81-42 was added, as IC 5 IC.
- Table 2 The activity of the compound was evaluated by 1) the concentration at which the absorbance in the presence of 2) ⁇ ) 8 and the absorbance in the presence of the test compound became 50 ⁇ ⁇ ⁇ ⁇ with respect to the absorbance when only Aj81-42 was added, as IC 5 IC.
- the compounds of the present invention selectively inhibited the activation of MacPharge by; 8 amyloid.
- the compounds of the present invention are useful as Alzheimer's disease drugs.
- cerebellar granule cells were prepared as follows. That is, the cerebellum was excised from a rat (Wistar, 7 days old: SLC in Japan), treated with papain (9 U / ml, 15 minutes) to disperse the cells, and a culture solution (MEM (Sigma)) , 20 mM KCK 20 mM Hepes. 103 ⁇ 4 FBS (GIBCO), 100 U / ml penici II in + 100 ⁇ g / ml streptomycin (Sigma)).
- MEM culture solution
- AraC (10 AtM: Sigma) was added, and the cells were used for the experiment on day 8 of the culture.
- intraperitoneal macrophages (prepared in the same manner as in Example 1) were added to the cerebellar granule cells on day 8 of culture, the cells were cultured, and 24 hours later, A3 1-42 (20 ⁇ g / ml: Sigma), and Test compounds were added. Nerve cell death was measured after incubation for 72 weeks.
- the experiment was performed in a culture solution containing mouse interferon ⁇ (250 U / ml: genzyme techne) and polymyxin B (10 ⁇ g / ml: Sigma).
- the neuronal cell death inhibitory activity of the compound was evaluated based on this value, which was defined as IC5 () at which the cell death was inhibited by 50% in the absence of the test compound.
- Test compound IC 50 (ig / m 1) Compound CH 2 0.5
- the compounds of the present invention inhibited A ⁇ -induced neuronal cell death due to macula phage activation.
- the compounds of the present invention are useful as drugs for Alzheimer's disease. (Formulation example))
- Each standard bipartite hard gelatin capsule contains 100 mg of Compound A in powder form, 150 mg of lactose, 50 mg of cellulose and 6 mg of magnesium stearate.
- a unit capsule is manufactured by filling the capsule, washed, and dried.
- the present invention relates to a drug for central diseases (particularly Alzheimer's disease) having excellent activity and Alzheimer's disease in which microglia is activated (particularly those in which microdary is activated by 8-amyloid) It is useful as a drug.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2457720A CA2457720C (en) | 2001-07-13 | 2002-07-11 | Medicine containing pyrimidine derivative |
EP02745972A EP1433480B1 (en) | 2001-07-13 | 2002-07-11 | Medicine containing pyrimidine derivative |
DK02745972.6T DK1433480T3 (da) | 2001-07-13 | 2002-07-11 | Lægemiddel indeholdende pyrimidin-derivat |
US10/483,674 US7425559B2 (en) | 2001-07-13 | 2002-07-11 | Medicine containing pyrimidine derivative |
JP2003511830A JP4398724B2 (ja) | 2001-07-13 | 2002-07-11 | ピリミジン誘導体を含有する医薬 |
AT02745972T ATE493988T1 (de) | 2001-07-13 | 2002-07-11 | Pyrimidinderivate enthaltendes medikament |
DE60238847T DE60238847D1 (de) | 2001-07-13 | 2002-07-11 | Pyrimidinderivate enthaltendes medikament |
AU2002318802A AU2002318802B2 (en) | 2001-07-13 | 2002-07-11 | Medicine containing pyrimidine derivative |
US12/222,599 US8288399B2 (en) | 2001-07-13 | 2008-08-12 | Medicine containing pyrimidine derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001213338 | 2001-07-13 | ||
JP2001-213338 | 2001-07-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003006024A1 true WO2003006024A1 (fr) | 2003-01-23 |
Family
ID=19048332
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/007060 WO2003006024A1 (fr) | 2001-07-13 | 2002-07-11 | Medicament contenant un derive de pyrimidine |
Country Status (10)
Country | Link |
---|---|
US (2) | US7425559B2 (ja) |
EP (1) | EP1433480B1 (ja) |
JP (1) | JP4398724B2 (ja) |
AT (1) | ATE493988T1 (ja) |
AU (1) | AU2002318802B2 (ja) |
CA (1) | CA2457720C (ja) |
DE (1) | DE60238847D1 (ja) |
DK (1) | DK1433480T3 (ja) |
ES (1) | ES2358888T3 (ja) |
WO (1) | WO2003006024A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60238847D1 (de) * | 2001-07-13 | 2011-02-17 | Btg Internat Ltd Company No 2664412 | Pyrimidinderivate enthaltendes medikament |
GB0917774D0 (en) * | 2009-10-09 | 2009-11-25 | Senexis Ltd | Novel pharmaceutical compounds |
GB0917775D0 (en) | 2009-10-09 | 2009-11-25 | Btg Int Ltd | Novel pharmaceutical compounds |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS51141896A (en) * | 1975-05-31 | 1976-12-07 | Sankyo Co Ltd | Process for preparing fused ring triazoropyrimidine derivatives |
JPS52116497A (en) * | 1976-03-26 | 1977-09-29 | Sankyo Co Ltd | Fused-ring triazolopyrimidine derivatives |
JPH0276880A (ja) * | 1988-06-16 | 1990-03-16 | Sankyo Co Ltd | 悪液質改善治療剤 |
WO2001042247A1 (fr) * | 1999-12-13 | 2001-06-14 | Eisai Co., Ltd. | Composes heterotricycliques fusionnes, procede de preparation de ces composes et medicaments contenant ces composes |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5353698A (en) | 1976-10-20 | 1978-05-16 | Sankyo Co Ltd | Pyrrolotriazolopyrimidine derivatives and their preparation |
JPS5353697A (en) | 1976-10-20 | 1978-05-16 | Sankyo Co Ltd | Tricyclic triazolopyrimidine derivatives |
JPS5368800A (en) | 1976-11-30 | 1978-06-19 | Sankyo Co Ltd | Cycloalkyl substd. pyrrolotriazolopyrimidine derivatives |
JPS5649391A (en) | 1979-09-28 | 1981-05-02 | Mochida Pharmaceut Co Ltd | Novel bis- 8h-pyrrolo- 3,2-e -s-triazolo- 1,5-a - pyrimidinomethyl amine derivative |
JPS5649385A (en) | 1979-09-29 | 1981-05-02 | Mochida Pharmaceut Co Ltd | Novel s-triazolo- 1,5-a -pyrimidine derivative |
JPS5735593A (en) | 1980-08-12 | 1982-02-26 | Mochida Pharmaceut Co Ltd | Novel pyrolo 3,2-e -s-triazolo 1,5-a pyrimidine derivative |
GB2138418B (en) | 1982-02-19 | 1985-12-04 | Mochida Pharm Co Ltd | Novel s-triazole(1,5-a)pyrimidine derivatives |
CA1330079C (en) | 1988-10-13 | 1994-06-07 | Michihiko Tsujitani | Pyrrolo (3,2-e)pyrazolo(1,5-a)pyrimidine derivative and medicine comprising the same |
JP3898296B2 (ja) | 1996-08-28 | 2007-03-28 | ポーラ化成工業株式会社 | ピロロピラゾロピリミジン化合物及びこれを有効成分とする医薬 |
JPH10218881A (ja) | 1997-02-03 | 1998-08-18 | Pola Chem Ind Inc | 新規なピロロピラゾロピリミジン誘導体 |
EP1012151B1 (en) * | 1997-09-02 | 2002-08-07 | Bristol-Myers Squibb Pharma Company | Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders |
WO1999050250A1 (en) | 1998-03-27 | 1999-10-07 | Janssen Pharmaceutica N.V. | Hiv inhibiting pyrimidine derivatives |
EP0945442A1 (en) | 1998-03-27 | 1999-09-29 | Janssen Pharmaceutica N.V. | Trisubstituted pyrimidine derivatives |
US6248739B1 (en) | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | Quinolinecarboxamides as antiviral agents |
SE0101523L (sv) | 2000-12-29 | 2002-06-30 | Artimplant Ab | Linjär polymer |
US6693125B2 (en) | 2001-01-24 | 2004-02-17 | Combinatorx Incorporated | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders |
FR2826011B1 (fr) | 2001-06-14 | 2004-12-10 | Oreal | Nouveaux derives de la 7-oxo-dhea et utilisation cosmetique |
DE60238847D1 (de) * | 2001-07-13 | 2011-02-17 | Btg Internat Ltd Company No 2664412 | Pyrimidinderivate enthaltendes medikament |
-
2002
- 2002-07-11 DE DE60238847T patent/DE60238847D1/de not_active Expired - Lifetime
- 2002-07-11 WO PCT/JP2002/007060 patent/WO2003006024A1/ja active Application Filing
- 2002-07-11 AT AT02745972T patent/ATE493988T1/de not_active IP Right Cessation
- 2002-07-11 US US10/483,674 patent/US7425559B2/en not_active Expired - Fee Related
- 2002-07-11 AU AU2002318802A patent/AU2002318802B2/en not_active Ceased
- 2002-07-11 DK DK02745972.6T patent/DK1433480T3/da active
- 2002-07-11 ES ES02745972T patent/ES2358888T3/es not_active Expired - Lifetime
- 2002-07-11 CA CA2457720A patent/CA2457720C/en not_active Expired - Fee Related
- 2002-07-11 EP EP02745972A patent/EP1433480B1/en not_active Expired - Lifetime
- 2002-07-11 JP JP2003511830A patent/JP4398724B2/ja not_active Expired - Fee Related
-
2008
- 2008-08-12 US US12/222,599 patent/US8288399B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS51141896A (en) * | 1975-05-31 | 1976-12-07 | Sankyo Co Ltd | Process for preparing fused ring triazoropyrimidine derivatives |
JPS52116497A (en) * | 1976-03-26 | 1977-09-29 | Sankyo Co Ltd | Fused-ring triazolopyrimidine derivatives |
JPH0276880A (ja) * | 1988-06-16 | 1990-03-16 | Sankyo Co Ltd | 悪液質改善治療剤 |
WO2001042247A1 (fr) * | 1999-12-13 | 2001-06-14 | Eisai Co., Ltd. | Composes heterotricycliques fusionnes, procede de preparation de ces composes et medicaments contenant ces composes |
Also Published As
Publication number | Publication date |
---|---|
DK1433480T3 (da) | 2011-04-11 |
US8288399B2 (en) | 2012-10-16 |
JPWO2003006024A1 (ja) | 2004-10-28 |
DE60238847D1 (de) | 2011-02-17 |
EP1433480B1 (en) | 2011-01-05 |
EP1433480A1 (en) | 2004-06-30 |
US20040242605A1 (en) | 2004-12-02 |
US20090005402A1 (en) | 2009-01-01 |
CA2457720C (en) | 2010-11-02 |
US7425559B2 (en) | 2008-09-16 |
ES2358888T3 (es) | 2011-05-16 |
AU2002318802B2 (en) | 2007-08-23 |
JP4398724B2 (ja) | 2010-01-13 |
EP1433480A4 (en) | 2005-10-05 |
CA2457720A1 (en) | 2003-01-23 |
AU2002318802A1 (en) | 2003-01-29 |
ATE493988T1 (de) | 2011-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5544484B2 (ja) | ジケトピペラジン類の使用方法とジケトピペラジン類を含む組成物 | |
JP6411680B1 (ja) | Lsd1阻害剤を用いて多発性硬化症を処置する方法 | |
US20200323828A1 (en) | Methods of treating behavior alterations | |
JP2002053566A (ja) | チアゾール化合物及びその医薬用途 | |
JP2004536111A (ja) | 4−(4−メトキシベンジル)−n′−(5−ニトロ−1,3−チアゾール−2−イル)尿素、およびグリコーゲン合成酵素キナーゼ−3(gsk3)に関連する症状の治療におけるその使用 | |
WO2001008705A1 (fr) | Remedes contre les douleurs neurogenes | |
WO2003006024A1 (fr) | Medicament contenant un derive de pyrimidine | |
WO2003084542A1 (fr) | Accelerateur de production d'un facteur neurotrophique | |
MXPA06015196A (es) | Tratamiento del dolor neuropatico, la fibromialgia o la artritis reumatoide. | |
RU2258506C2 (ru) | Лекарственные средства для предупреждения и лечения нейродегенеративных заболеваний | |
CN113631164A (zh) | 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法 | |
JP2023501967A (ja) | d-アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス | |
JP2003089645A (ja) | ピリミジン誘導体を含有する医薬 | |
US6358966B2 (en) | Treatment of depression | |
WO2003084572A1 (fr) | Composition médicale comprenant un inhibiteur de l'acat et agent améliorant la résistance à l'insuline | |
KR102676216B1 (ko) | 신규 중추-작용성 그렐린 효능제 및 그의 의학적 용도 | |
WO2024105225A1 (en) | Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain | |
TW202334143A (zh) | 結晶咪唑并[4,5-b]吡啶化合物、醫藥組合物及彼等治療醫學症狀之用途 | |
JPH06298738A (ja) | 5−アミノピラゾール誘導体 | |
WO2007026928A1 (ja) | 神経因性疼痛治療剤 | |
JPH06287180A (ja) | アミジノインダゾール誘導体 | |
JP2019502679A (ja) | アルツハイマー病及び/または脳アミロイド血管症の処置のための新規の化合物及び方法 | |
MXPA01002661A (en) | Treatment of depression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003511830 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002745972 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2457720 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002318802 Country of ref document: AU |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10483674 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2002745972 Country of ref document: EP |